Meeker David P 4
4 · RHYTHM PHARMACEUTICALS, INC. · Filed Feb 4, 2025
Insider Transaction Report
Form 4
Meeker David P
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2025-02-01+14,125→ 194,205 total - Sale
Common Stock
2025-02-04$59.43/sh−4,278$254,242→ 189,927 total - Exercise/Conversion
Restricted Stock Units
2025-02-01−14,125→ 28,250 total→ Common Stock (14,125 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
- [F3]Includes 5,475 additional shares acquired under the Issuer's Employee Stock Purchase Plan.
- [F4]The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.